CIR, NRM, RFS, and OS for MRD⁺and MRD⁻patients. (A) CIR and NRM by competing risk analysis for MRD⁺ (n = 43) and MRD⁻ patients (n = 53). (B) RFS for MRD⁺ positive (n = 43) and MRD⁻ patients (n = 53). (C) OS for MRD⁺ (n = 43) and MRD⁻ patients (n = 53).